The value of progression-free survival to patients with advanced-stage cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://www.nature.com/articles/nrclinonc.2011.156.pdf
Reference51 articles.
1. Booth, C. M. & Tannock, I. Reflections on medical oncology: 25 years of clinical trials—where have we come and where are we going? J. Clin. Oncol. 26, 6–8 (2008).
2. Soria, J. C., Massard, C. & Le Chevalier, T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann. Oncol. 21, 2324–2332 (2010).
3. Sargent, D. J. & Hayes, D. F. Assessing the measure of a new drug: is survival the only thing that matters? J. Clin. Oncol. 26, 1922–1923 (2008).
4. Peppercorn, J. M. et al. American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J. Clin. Oncol. 29, 755–760 (2011).
5. Burstein, H. J. Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J. Clin. Oncol. 29, 1232–1235 (2011).
Cited by 65 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study;Frontiers in Pharmacology;2024-09-06
2. Is the Homologous Recombination Repair Mutation Defined by a 15-Gene Panel Associated with the Prognosis of Epithelial Ovarian Cancer?;Molecular Diagnosis & Therapy;2024-07-05
3. Methodological Quality of Clinical Trials in Amyotrophic Lateral Sclerosis: A Systematic Review;Journal of Neuromuscular Diseases;2024-07-02
4. Peripheral Immune Profiles Predict ALS Progression in an Age- and Sex-Dependent Manner;Neurology Neuroimmunology & Neuroinflammation;2024-05
5. Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting;European Journal of Cancer;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3